| Interpretive Data: |
Refer to report
This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.
Refer to Statement B under Testing Information at http://www.aruplab.com.
|
| Note: |
This test is designed to detect exon 19 deletions and the exon 21 L858R point mutation. These mutations account for about 90 percent of all reported EGFR mutations.
|
| CPT Code(s): |
88381 Microdissection; 83907 Lysis; 83898 x2 Amplification; 83892 Digestion; 83909 Separation and identification; 83896 x2 Nucleic acid probes; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test oncologic or inherited disorders.
|
Cross References: |
ERBB1 (EGFR Mutation Detection by PCR and Fragment Analysis), Erlotinib Responsiveness in NSCLC (EGFR Mutation Detection by PCR and Fragment Analysis), Gefitinib Responsiveness in NSCLC (EGFR Mutation Detection by PCR and Fragment Analysis), IRESSA Responsiveness in NSCLC (EGFR Mutation Detection by PCR and Fragment Analysis), Non-small Cell Lung Cancer (NSCLC) Therapeutic Panel: EGFR Mutation Analysis and ALK FISH Analysis (EGFR Mutation Detection by PCR and Fragment Analysis)
, NSCLC or Non Small-Cell Lung Cancer (EGFR Mutation Detection by PCR and Fragment Analysis), Tarceva Responsiveness in NSCLC (EGFR Mutation Detection by PCR and Fragment Analysis) |